Efficacy and Safety of Ticagrelor: A Reversible P2Y12 Receptor Antagonist
Annals of Pharmacotherapy2010Vol. 44(3), pp. 524–537
Citations Over TimeTop 10% of 2010 papers
Abstract
Ticagrelor's improved pharmacokinetic and pharmacodynamic profile builds upon the limitations of currently available P2Y12 receptor antagonists. Ticagrelor represents a promising approach for the prevention of cardiovascular events in patients with ACS.
Related Papers
- → Comparison of patient intake of ticagrelor, prasugrel, or clopidogrel on restoring platelet function by donor platelets(2015)24 cited
- → P2Y12 receptor inhibition with prasugrel and ticagrelor in STEMI patients after fibrinolytic therapy: Analysis from the SAMPA randomized trial(2016)14 cited
- → Ticagrelor or prasugrel in STEMI patients: a pharmacodynamic evaluation(2013)
- → Acute coronary syndrome: potent oral antiplatelets(2013)
- → ANTI-THROMBOCYTIC DRUGS FOR ACUTE CORONARY SYNDROME: DIRECT COMPARISON OF HEMORRHAGIC SAFETY THROMBOCYTE P2Y12-RECEPTOR BLOCKERS TICAGRELOR AND CLOPIDROGEL (BASED ON PLATO STUDY RESULTS(2016)